Recent Company News

• 01:17 PM ET Jul 09, 2026
  

  Transcript Intelligence: Belite Bio at Piper Sandler Virtual Ophthalmology Investor Symposium ($152.01, -0.29)

• 04:31 AM ET Jun 13, 2026
  

  Belite Bio completes rolling submission of NDA for tinlarebant to treat STGD1 to FDA ($138.16, 0.00)

• 05:50 PM ET Jun 08, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:39 PM ET Jun 08, 2026
  

  Transcript Intelligence: Belite Bio at Goldman Sachs Global Healthcare Conference ($139.63, -3.72)

• 01:17 PM ET May 26, 2026
  

  Transcript Intelligence: Belite Bio at Stifel Virtual Ophthalmology Forum ($136.97, -0.33)

• 09:18 PM ET May 22, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 05:30 PM ET May 20, 2026
  

  Transcript Intelligence: Belite Bio Q1 Earnings Guidance

• 05:30 PM ET May 20, 2026
  

  Transcript Intelligence: Belite Bio Q1 Earnings Themes

• 05:30 PM ET May 20, 2026
  

  Transcript Intelligence: Belite Bio Q1 Earnings Q&A

• 06:01 AM ET May 20, 2026
  

  Belite Bio reports Q1 EPS ($0.45) vs FactSet ($0.63) [8 est, ($0.96)-(0.47)] ($139.70, 0.00)